Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction

Blood

Volumn 100, Issue 4, 2002, Pages 1265-1273

  Uherek, Christoph ^a,b,c   Tonn, Torsten ^a,b,c   Uherek, Barbara ^a,b,c   Becker, Sven ^a,b,c   Schnierle, Barbara ^a,b,c   Klingemann, Hans Georg ^a,b,c   Wels, Winfried ^a,b,c  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^b Institute for Transfusion Medicine and Immunohematology   (Germany)

^c RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD8 ANTIGEN; HYBRID PROTEIN; RETROVIRUS VECTOR; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CELL LINE; CELL SURFACE; CONTROLLED STUDY; CYTOLYSIS; DNA MODIFICATION; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; NATURAL KILLER CELL; ONCOGENE NEU; PRIORITY JOURNAL; TARGET CELL DESTRUCTION; TUMOR CELL DESTRUCTION;

EID: 0037103311     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v100.4.1265.h81602001265_1265_1273     Document Type: Article

References (58)

1. Adoptive transfer studies demonstrating the antiviral effect of natural killer cells in vivo
2. High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2
3. Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-gamma production, and expansion of natural killer cells
4. Depressed ability of patients with melanoma or renal cell carcinoma to generate adherent lymphokine-activated killer cells
5. Natural killer cells and tumor therapy
6. HLA-G HLA-E: Fundamental and pathophysiological aspects
7. Regulation of the natural killer cell receptor repertoire
8. A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia
9. Patients with melanoma metastases at cutaneous and subcutaneous sites are highly susceptible to interleukin-2-based therapy
10. A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma
11. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia
12. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma
13. Injury to autologous normal tissues and tumors mediated by lymphokine-activated killer (LAK) cells generated in vitro from peripheral blood mononuclear cells of glioblastoma patients
14. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies
15. IL-2/LAK therapy for refractory acute monoblastic leukemia relapsing after unrelated allogeneic bone marrow transplantation
16. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer
17. The inhibition of lymphokine-activated killer cells in acute myeloblastic leukemia is mediated by transforming growth factor-beta 1
18. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood
19. Antileukemia activity of a natural killer cell line against human leukemias
20. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92
21. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells
22. Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor
23. Adoptive cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92
24. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis
25. Specific lysis of tumor cells by an NK-like cell line transfected with chimeric receptor genes
26. Chimeric zeta-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes
27. Antigen specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains
28. Biochemical and clinical implications of the ErbB/ HER signaling network of growth factor receptors
29. New EMBO members review: The ErbB signaling network: Receptor heterodimerization in development and cancer
30. Intervention in receptor tyrosine kinase-mediated pathways: Recombinant antibody fusion proteins targeted to ErbB2
31. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
32. Construction, bacterial expression and characterization of a bifunctional single-chain antibody-phosphatase fusion protein targeted to the human erbB-2 receptor
33. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors
34. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells
35. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions
36. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity
37. Tumor-specific T-bodies: Towards clinical application
38. Chimeric antigen receptors for the retargeting of cytotoxic effector cells
39. Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes
40. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression
41. Systemic treatment with a recombinant erbB-2 receptor-specific tumor toxin efficiently reduces pulmonary metastases in mice injected with genetically modified carcinoma cells
42. Stable expression of the ecotropic retrovirus receptor in amphotropic packaging cells facilitates the transfer of recombinant vectors and enhances the yield of retroviral particles
43. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product
44. Improved retroviral vectors for gene transfer and expression
45. Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2
46. Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells
47. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor
48. EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins
49. Synergistic interaction between an anti-p185HER-2 Pseudomonas exotoxin fusion protein [scFv-(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2
50. Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists
51. + hematopoietic progenitor cells with recombinant immunotoxins
52. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection
53. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects
54. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy
55. Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production
56. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues
57. Pharmacological control of antigen responsiveness in genetically modified T lymphocytes
58. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia